New drug TLC-2716 slashes remnant cholesterol in first human trial
In a 14-day phase 1 trial, healthy volunteers taking TLC-2716 showed up to 38.5% lower triglycerides and up to 61% lower remnant cholesterol after meals, by inhibiting LXRα activity in the liver and gut. The oral drug was safe and well tolerated, suggesting potential for treating cardiometabolic disease, but longer studies in overweight/obese individuals with poor lipid profiles are needed to confirm benefits.